Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Maat Pharma's Enterprise Value is €44.64 Mil.
Maat Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-15.72 Mil. Therefore, Maat Pharma's EV-to-OCF for today is -2.84.
The historical rank and industry rank for Maat Pharma's EV-to-OCF or its related term are showing as below:
XPAR:MAAT'
s EV-to-OCF Range Over the Past 10 Years
Min: -7.28 Med: -3.29 Max: 2.28
Current: -2.91
During the past 8 years, the highest EV-to-OCF of Maat Pharma was 2.28. The lowest was -7.28. And the median was -3.29.
XPAR:MAAT's EV-to-OCF is ranked worse than 54.05% of 1406
companies
in the Biotechnology industry
Industry Median: -3.7
vs XPAR:MAAT: -2.91
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Maat Pharma's PE Ratio (TTM) for today is calculated as:
Maat Pharma's share price for today is €2.88.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Maat Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Maat Pharma EV-to-OCF Related Terms
Maat Pharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Maat Pharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:MAAT vs VRTX, REGN, MRNA: EV-to-OCF Comparison
For the Biotechnology subindustry, Maat Pharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maat Pharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maat Pharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Maat Pharma's EV-to-OCF falls into.
Maat Pharma's current Enterprise Value is €44.64 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Maat Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-15.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maat Pharma (XPAR:MAAT) has a EV-to-OCF of -2.84 as of Sep. 08, 2026. According to the industry distribution chart, Maat Pharma ranks #760 out of 1406 companies in the Biotechnology industry, placing it in the top 54.1%.
Is Maat Pharma's EV-to-OCF too high?
Maat Pharma's current EV-to-OCF is -2.84. Based on the distribution chart, Maat Pharma ranks #760 out of 1406 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Maat Pharma has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Maat Pharma's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Maat Pharma ranks #760 out of 1406 companies for EV-to-OCF. This places Maat Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Maat Pharma's current EV-to-OCF is -2.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Maat Pharma (XPAR:MAAT) is currently considered Possible Value Trap. The stock's GF Value™ is €10.87, compared to a current price of €2.88 — trading 73.5% below its estimated fair value. The current EV-to-OCF is -2.84. Maat Pharma's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Maat Pharma (XPAR:MAAT), the current EV-to-OCF is -2.84 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maat Pharma (XPAR:MAAT) Overvalued in 2026?
Based on GuruFocus' analysis, Maat Pharma stock appears to be undervalued.
The current stock price of €2.88 is trading 73.5% below its estimated GF Value™ of €10.87.
GuruFocus considers Maat Pharma to be Possible Value Trap.
Key valuation signals for XPAR:MAAT:
EV-to-OCF: -2.84
GF Value™: €10.87 vs. price of €2.88 (73.5% below fair value)
No single metric tells the full story. See the XPAR:MAAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.
29GF Score
Get the complete analysis for XPAR:MAAT
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MAAT has been successfully added to your 
